$Alemtuzumab in the Treatment of Refractory Acute Rejection and Bronchiolitis Obliterans Syndrome After Human Lung Transplantation$

Alemtuzumab in the Treatment of Refractory Acute Rejection and Bronchiolitis Obliterans Syndrome After Human Lung Transplantation

Despite substantial improvements in early survival after lung transplantation, refractory acute rejection (RAR) and bronchiolitis obliterans syndrome (BOS) remain major contributors to transplant‐related morbidity and mortality. We have utilized alemtuzumab, a humanized anti‐CD52 antibody which resu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2007-12, Vol.7 (12), p.2802-2808
Hauptverfasser:	Reams, B. D., Musselwhite, L. W., Zaas, D. W., Steele, M. P., Garantziotis, S., Eu, P. C., Snyder, L. D., Curl, J., Lin, S. S., Davis, R. D., Palmer, S. M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute rejection Adolescent Adult Aged Alemtuzumab Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antibodies, Neoplasm - therapeutic use Antigens, CD - immunology Antigens, Neoplasm - immunology Biological and medical sciences Biopsy Bronchiolitis Obliterans - drug therapy Bronchiolitis Obliterans - etiology Bronchiolitis Obliterans - pathology bronchiolitis obliterans syndrome CD4-Positive T-Lymphocytes - drug effects CD4-Positive T-Lymphocytes - pathology CD52 Antigen Chronic obstructive pulmonary disease, asthma Female Forced Expiratory Volume - physiology Glycoproteins - immunology Graft Rejection - drug therapy Graft Rejection - etiology Graft Rejection - pathology Humans Kaplan-Meier Estimate Lung - pathology Lung - physiopathology Lung - surgery lung transplantation Lung Transplantation - adverse effects Male Medical sciences Middle Aged Pneumology Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!